newsfilter
← Latest News
GlobeNewswire·

Cingulate Initiates Final Study for Lead ADHD Asset CTx-1301

KANSAS CITY, Kan., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology